Literature DB >> 16003067

Ubiquitin immunoreactivity in cerebrospinal fluid after traumatic brain injury: clinical and experimental findings.

Matthias Majetschak1, David R King, Ulrich Krehmeier, Lissette T Busby, Claudius Thome, Susanne Vajkoczy, Kenneth G Proctor.   

Abstract

OBJECTIVE: Recent data indicate that ubiquitin is increased in serum after trauma and might regulate immune functions. Its cellular source is unknown. Because there have been no previous studies after traumatic brain injury (TBI), we determined whether ubiquitin immunoreactivity is increased in cerebrospinal fluid (CSF) after TBI. DESIGN AND
SETTING: Prospective observational study of patients, with a subsequent interventional study of animals.
SUBJECTS: The subjects were 14 patients with TBI, five patients with nontraumatic subarachnoid hemorrhage, ten nonneurologic controls, and seven cross-bred swine.
INTERVENTIONS: Standardized TBI.
MEASUREMENTS AND MAIN RESULTS: Ubiquitin immunoreactivity was analyzed by enzyme-linked immunosorbent assay and immunoblotting. Hemolysis was assessed spectrophotometrically. CSF ubiquitin levels (mean +/- sd) were 19 +/- 3 ng/mL in nonneurologic control patients, 81 +/- 48 ng/mL at 7 +/- 2 hrs after TBI (p = .002), and at the end of operation in patients with nontraumatic subarachnoid hemorrhage they were 104 +/- 68 ng/mL (p = .001). CSF and serum ubiquitin were measured for 7 days in six patients with TBI. In survivors (n = 3), CSF ubiquitin levels progressively recovered, whereas in nonsurvivors (n = 3), the levels increased until death. There was no difference in serum ubiquitin levels between survivors/nonsurvivors and there was no correlation between serum and CSF ubiquitin levels. In swine, CSF ubiquitin levels peaked at 8- to 30-fold higher than baseline at 60 min post-TBI and then declined with a half-life of 1.3 hrs. In CSF with hemolysis, peak ubiquitin levels were five-fold higher than without hemolysis (p < .05). Ubiquitin and hemoglobin correlations in CSF and after in vitro lysis of erythrocytes suggested that erythrolysis could account for no more than 23 +/- 16% of the CSF ubiquitin.
CONCLUSIONS: CSF ubiquitin levels are increased more than four-fold in patients after TBI and nontraumatic subarachnoid hemorrhage. Peak CSF ubiquitin measurements in patients with TBI probably underestimated the actual peak, on the basis of data from the animal model. The progressive rise in CSF ubiquitin in patients with TBI who died suggests that lack of clearance could reflect lethal progression to irreversible brain damage. Erythrolysis is one potential source of CSF ubiquitin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003067     DOI: 10.1097/01.ccm.0000169883.41245.23

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

1.  Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury.

Authors:  Linda Papa; Linnet Akinyi; Ming Cheng Liu; Jose A Pineda; Joseph J Tepas; Monika W Oli; Wenrong Zheng; Gillian Robinson; Steven A Robicsek; Andrea Gabrielli; Shelley C Heaton; H Julia Hannay; Jason A Demery; Gretchen M Brophy; Joe Layon; Claudia S Robertson; Ronald L Hayes; Kevin K W Wang
Journal:  Crit Care Med       Date:  2010-01       Impact factor: 7.598

2.  Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury.

Authors:  Stefania Mondello; Akinyi Linnet; Andras Buki; Steven Robicsek; Andrea Gabrielli; Joseph Tepas; Linda Papa; Gretchen M Brophy; Frank Tortella; Ronald L Hayes; Kevin K Wang
Journal:  Neurosurgery       Date:  2012-03       Impact factor: 4.654

3.  Exogenous ubiquitin reduces inflammatory response and preserves myocardial function 3 days post-ischemia-reperfusion injury.

Authors:  Stephanie L C Scofield; Suman Dalal; Kristina A Lim; Patsy R Thrasher; Christopher R Daniels; Jonathan M Peterson; Mahipal Singh; Krishna Singh
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-01-25       Impact factor: 4.733

4.  Increased ISGylation in Cases of TBI-Exposed ALS Veterans.

Authors:  Joshua Schwartzenburg; Meredith Juncker; Ryan Reed; Shyamal Desai
Journal:  J Neuropathol Exp Neurol       Date:  2019-03-01       Impact factor: 3.685

5.  Extracellular ubiquitin modulates cardiac fibroblast phenotype and function via its interaction with CXCR4.

Authors:  Stephanie L C Scofield; Christopher R Daniels; Suman Dalal; Jonathan A Millard; Mahipal Singh; Krishna Singh
Journal:  Life Sci       Date:  2018-09-05       Impact factor: 5.037

6.  Ubiquitin and stromal cell-derived factor-1α in bronchoalveolar lavage fluid after burn and inhalation injury.

Authors:  Todd A Baker; Christopher S Davis; Harold H Bach; Jacqueline Romero; Ellen L Burnham; Elizabeth J Kovacs; Richard L Gamelli; Matthias Majetschak
Journal:  J Burn Care Res       Date:  2012 Jan-Feb       Impact factor: 1.845

7.  CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin.

Authors:  Vikas Saini; Adriano Marchese; Matthias Majetschak
Journal:  J Biol Chem       Date:  2010-03-12       Impact factor: 5.157

8.  Initial assessment of the role of CXC chemokine receptor 4 after polytrauma.

Authors:  Harold H Bach; Vikas Saini; Todd A Baker; Abhishek Tripathi; Richard L Gamelli; Matthias Majetschak
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

9.  Extracellular ubiquitin inhibits beta-AR-stimulated apoptosis in cardiac myocytes: role of GSK-3beta and mitochondrial pathways.

Authors:  Mahipal Singh; Marina Roginskaya; Suman Dalal; Bindu Menon; Ekaterina Kaverina; Marvin O Boluyt; Krishna Singh
Journal:  Cardiovasc Res       Date:  2009-12-16       Impact factor: 10.787

10.  Exogenous ubiquitin modulates chronic β-adrenergic receptor-stimulated myocardial remodeling: role in Akt activity and matrix metalloproteinase expression.

Authors:  Christopher R Daniels; Cerrone R Foster; Sana Yakoob; Suman Dalal; William L Joyner; Mahipal Singh; Krishna Singh
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-05       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.